Literature DB >> 10724216

Treatment of epidermolysis bullosa simplex (EBS) with tetracycline.

N K Veien, S K Buus.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10724216     DOI： 10.1001/archderm.136.3.424-a

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN： 0003-987X


× No keyword cloud information.
  4 in total

1.  Persistent release of IL-1s from skin is associated with systemic cardio-vascular disease, emaciation and systemic amyloidosis: the potential of anti-IL-1 therapy for systemic inflammatory diseases.

Authors:  Keiichi Yamanaka; Takehisa Nakanishi; Hiromitsu Saito; Junko Maruyama; Kenichi Isoda; Ayumu Yokochi; Kyoko Imanaka-Yoshida; Kenshiro Tsuda; Masato Kakeda; Ryuji Okamoto; Satoshi Fujita; Yoichiro Iwakura; Noboru Suzuki; Masaaki Ito; Kazuo Maruyama; Esteban C Gabazza; Toshimichi Yoshida; Motomu Shimaoka; Hitoshi Mizutani
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

2.  MMP-9 and CXCL8/IL-8 are potential therapeutic targets in epidermolysis bullosa simplex.

Authors:  Thomas Lettner; Roland Lang; Alfred Klausegger; Stefan Hainzl; Johann W Bauer; Verena Wally
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240

3.  Cut and Paste: Efficient Homology-Directed Repair of a Dominant Negative KRT14 Mutation via CRISPR/Cas9 Nickases.

Authors:  Thomas Kocher; Patricia Peking; Alfred Klausegger; Eva Maria Murauer; Josefina Piñón Hofbauer; Verena Wally; Thomas Lettner; Stefan Hainzl; Michael Ablinger; Johann Wolfgang Bauer; Julia Reichelt; Ulrich Koller
Journal:  Mol Ther       Date:  2017-08-24       Impact factor: 11.454

4.  Basal pharmacokinetic parameters of topically applied diacerein in pediatric patients with generalized severe epidermolysis bullosa simplex.

Authors:  Michael Ablinger; Thomas K Felder; Monika Wimmer; Roland Zauner; Peter Hofbauer; Thomas Lettner; Martin Wolkersdorfer; Florian B Lagler; Anja Diem; Johann W Bauer; Verena Wally
Journal:  Orphanet J Rare Dis       Date:  2018-11-01       Impact factor: 4.123
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.